Revenue $3.75B, up 4.6% on a year earlier. Adjusted R&D as % of Total Revenues $6.00M, up 0.0%. Adjusted SG&A as % of Total Revenues $22.00M, down 4.3%. Diluted EPS -$0.10 against $0.00.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $3.75B | $3.52B | $3.58B | +4.6% |
| Operating income | $6.30M | -$79.70M | $233.00M | -97.3% |
| Net income | -$118.80M | $176.40M | -$4.60M | |
| Diluted EPS | -$0.10 | $0.15 | $0.00 | |
| Operating cash flow | $381.80M | $388.30M | $219.70M | +73.8% |
| Capital expenditures | -$52.80M | -$39.90M | -$52.90M | |
| Free cash flow | $329.00M | $348.40M | $166.80M | +97.2% |
| Dividend per share | $0.12 | $0.12 | $0.12 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Adjusted R&D as % of Total Revenues | $6.00M | $6.00M | +0.0% |
| Adjusted SG&A as % of Total Revenues | $22.00M | $23.00M | -4.3% |
| Brands Net Sales | $2.42B | $2.28B | +5.9% |
| Developed Markets Net Sales | $2.19B | $2.12B | +3.5% |
| Emerging Markets Net Sales | $542.30M | $555.10M | -2.3% |
| Generics Net Sales | $1.33B | $1.28B | +3.3% |
| Greater China net sales | $713.80M | $588.90M | +21.2% |
| JANZ Net Sales | $296.10M | $305.70M | -3.1% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Viatris (VTRS) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/VTRS/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
